卡培他滨-话题@MedSci

#卡培他滨#

72篇内容 | 1719人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1293490, encodeId=027a1293490d6, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=ASCO 2014：卡培他滨联合PA-MSHA治疗转移性乳腺癌安全性良好, objectType=article, longId=35695, objectId=e63635695e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e63635695e4, replyNumber=0, likeNumber=54, createdTime=2014-06-02, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e63635695e4, moduleTitle=ASCO 2014：卡培他滨联合PA-MSHA治疗转移性乳腺癌安全性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e63635695e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293489, encodeId=252e12934890a, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=ASCO 2014：TX+卡培他滨序贯治疗可提高转移性乳腺癌生存, objectType=article, longId=35642, objectId=804e35642cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=804e35642cc, replyNumber=0, likeNumber=38, createdTime=2014-06-02, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=804e35642cc, moduleTitle=ASCO 2014：TX+卡培他滨序贯治疗可提高转移性乳腺癌生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=804e35642cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293488, encodeId=64a712934881d, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=GCS 2014：序贯卡培他滨加贝伐单抗维持治疗对转移性结直肠癌有获益（CAIRO3试验）, objectType=article, longId=31289, objectId=c813312897c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c813312897c, replyNumber=0, likeNumber=35, createdTime=2014-03-01, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c813312897c, moduleTitle=GCS 2014：序贯卡培他滨加贝伐单抗维持治疗对转移性结直肠癌有获益（CAIRO3试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c813312897c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293487, encodeId=ce8c129348e1c, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=GICS 2014：卡培他滨/替莫唑胺治疗抵抗性神经内分泌瘤效果更好, objectType=article, longId=31093, objectId=5c5431093d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c5431093d1, replyNumber=0, likeNumber=37, createdTime=2014-02-26, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c5431093d1, moduleTitle=GICS 2014：卡培他滨/替莫唑胺治疗抵抗性神经内分泌瘤效果更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c5431093d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293486, encodeId=52b01293486d3, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=GCS 2014：直肠癌术前口服卡培他滨化疗效果与输注5-FU相似, objectType=article, longId=29827, objectId=18072982e65, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18072982e65, replyNumber=0, likeNumber=27, createdTime=2014-01-24, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18072982e65, moduleTitle=GCS 2014：直肠癌术前口服卡培他滨化疗效果与输注5-FU相似, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18072982e65)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293485, encodeId=9397129348558, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JCO：舒尼替尼联合卡培他滨治疗转移性乳腺癌结果令人失望, objectType=article, longId=22856, objectId=23e822856c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23e822856c7, replyNumber=0, likeNumber=0, createdTime=2013-08-12, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23e822856c7, moduleTitle=JCO：舒尼替尼联合卡培他滨治疗转移性乳腺癌结果令人失望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23e822856c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293484, encodeId=4f991293484c9, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet Oncol：在卡培他滨-顺铂基础上联用西妥昔单抗不能改善晚期胃癌患者临床预后, objectType=article, longId=18831, objectId=158c1883170, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=158c1883170, replyNumber=0, likeNumber=48, createdTime=2013-05-18, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=158c1883170, moduleTitle=Lancet Oncol：在卡培他滨-顺铂基础上联用西妥昔单抗不能改善晚期胃癌患者临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=158c1883170)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293483, encodeId=6e0512934836d, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=卡培他滨化放疗用于局部胰腺癌疗效佳, objectType=article, longId=15335, objectId=c324153351d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c324153351d, replyNumber=0, likeNumber=41, createdTime=2013-02-20, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c324153351d, moduleTitle=卡培他滨化放疗用于局部胰腺癌疗效佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c324153351d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293482, encodeId=8f05129348284, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=SABCS：艾日布林用于晚期乳腺癌可与卡培他滨相媲美, objectType=article, longId=12837, objectId=5bfe1283efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bfe1283efa, replyNumber=0, likeNumber=30, createdTime=2012-12-12, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bfe1283efa, moduleTitle=SABCS：艾日布林用于晚期乳腺癌可与卡培他滨相媲美, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bfe1283efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293481, encodeId=07de12934815a, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=BMC Cancer:拉帕替尼+卡培他滨对某些乳腺癌伴或不伴脑转移患者疗效相同, objectType=article, longId=8453, objectId=937c84530c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=937c84530c, replyNumber=0, likeNumber=44, createdTime=2012-08-03, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=937c84530c, moduleTitle=BMC Cancer:拉帕替尼+卡培他滨对某些乳腺癌伴或不伴脑转移患者疗效相同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=937c84530c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293480, encodeId=9e3a12934809d, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=ASCO:T-DM1治疗进展期HER2阳性乳腺癌优于卡培他滨+拉帕替尼, objectType=article, longId=6777, objectId=f36c6e7786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f36c6e7786, replyNumber=0, likeNumber=29, createdTime=2012-06-07, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f36c6e7786, moduleTitle=ASCO:T-DM1治疗进展期HER2阳性乳腺癌优于卡培他滨+拉帕替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f36c6e7786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293479, encodeId=eb2a12934e99d, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JCO：沙利度胺+卡培他滨可使晚期肝癌pCR, objectType=article, longId=6600, objectId=516466003a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=516466003a, replyNumber=0, likeNumber=52, createdTime=2012-05-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=516466003a, moduleTitle=JCO：沙利度胺+卡培他滨可使晚期肝癌pCR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=516466003a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293478, encodeId=f83712934e81c, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=NICE指南草案不推荐贝伐珠单抗/卡培他滨治疗乳腺癌, objectType=article, longId=5675, objectId=80c556e5f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80c556e5f1, replyNumber=0, likeNumber=36, createdTime=2012-04-22, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80c556e5f1, moduleTitle=NICE指南草案不推荐贝伐珠单抗/卡培他滨治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80c556e5f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293477, encodeId=947d12934e764, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=CSCO:塞来昔布预防卡培他滨所致手足综合征, objectType=article, longId=3170, objectId=a62731e008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a62731e008, replyNumber=0, likeNumber=37, createdTime=2011-10-16, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a62731e008, moduleTitle=CSCO:塞来昔布预防卡培他滨所致手足综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a62731e008)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡培他滨

2020-05-29

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

ASCO 2014：卡培他滨联合PA-MSHA治疗转移性乳腺癌安全性良好

2014-06-02

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

ASCO 2014：TX+卡培他滨序贯治疗可提高转移性乳腺癌生存

2014-06-02

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

GCS 2014：序贯卡培他滨加贝伐单抗维持治疗对转移性结直肠癌有获益（CAIRO3试验）

2014-03-01

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

GICS 2014：卡培他滨/替莫唑胺治疗抵抗性神经内分泌瘤效果更好

2014-02-26

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

GCS 2014：直肠癌术前口服卡培他滨化疗效果与输注5-FU相似

2014-01-24

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JCO：舒尼替尼联合卡培他滨治疗转移性乳腺癌结果令人失望

2013-08-12

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet Oncol：在卡培他滨-顺铂基础上联用西妥昔单抗不能改善晚期胃癌患者临床预后

2013-05-18

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

卡培他滨化放疗用于局部胰腺癌疗效佳

2013-02-20

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

SABCS：艾日布林用于晚期乳腺癌可与卡培他滨相媲美

2012-12-12

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

BMC Cancer:拉帕替尼+卡培他滨对某些乳腺癌伴或不伴脑转移患者疗效相同

2012-08-03

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

ASCO:T-DM1治疗进展期HER2阳性乳腺癌优于卡培他滨+拉帕替尼

2012-06-07

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JCO：沙利度胺+卡培他滨可使晚期肝癌pCR

2012-05-27

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

NICE指南草案不推荐贝伐珠单抗/卡培他滨治疗乳腺癌

2012-04-22

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

CSCO:塞来昔布预防卡培他滨所致手足综合征

2011-10-16

科室
- - 订阅+
  - 更多科室
工具
服务